FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

| OMB Number:              | 3235-0287 |
|--------------------------|-----------|
| Estimated average burder | 1         |
| hours per response:      | 0.5       |

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| affirmative defer<br>10b5-1(c). See I                           | ise conditions of Rule instruction 10. |          |  |   |
|---|--|----------|--|---|
| 1. Name and Address of Reporting Person *  DRISCOLL FREDERICK W |  |          | 2. Issuer Name and Ticker or Trading Symbol Cellectar Biosciences, Inc. [ CLRB ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner   |
| (Last)  | (First)                                | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 02/14/2025                      | Officer (give title Other (specify below) below)  |
| C/O CELLECTAR BIOSCIENCES, INC. 100 CAMPUS DRIVE (Street)       |  |          | If Amendment, Date of Original Filed (Month/Day/Year)                            | 6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person |
| FLORHAM<br>PARK   | NJ                                     | 07932    |  |   |
| (City)  | (State)                                | (Zip)    |  |   |

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Titl | 1. Title of Security (Instr. 3) | Date<br>(Month/Day/Year) | if any<br>(Month/Day/Year) | Transaction Code (Instr. |   | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |               |       | Securities<br>Beneficially Owned<br>Following Reported | 6. Ownership<br>Form: Direct (D)<br>or Indirect (I)<br>(Instr. 4) | Beneficial<br>Ownership |
|---------|---------------------------------|--------------------------|----------------------------|--------------------------|---|---|---------------|-------|--|---|-------------------------|
|         |                                 |                          |                            | Code                     | v | Amount  | (A) or<br>(D) | Price | Transaction(s) (Instr. 3 and 4)                        |   | (Instr. 4)              |

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security (Instr.<br>3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security |            | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transaction<br>Code (Instr.<br>8) |   | 5. Number of<br>Derivative<br>Securities<br>Acquired (A) or<br>Disposed of<br>(D) (Instr. 3, 4<br>and 5) |     | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount of<br>Securities Underlying<br>Derivative Security (Instr.<br>3 and 4) |                                     | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---|---|------------|---|---|---|--|-----|--|--------------------|--|-------------------------------------|---|--|--|--|
|   |   |            |   | Code                                    | v | (A)  | (D) | Date<br>Exercisable  | Expiration<br>Date | Title  | Amount<br>or<br>Number<br>of Shares |   | Transaction(s)<br>(Instr. 4)   |  |  |
| Stock option<br>(right to buy)                      | \$0.29  | 02/14/2025 |   | A                                       |   | 60,000   |     | (1)  | 02/14/2035         | Common<br>Stock  | 60,000                              | \$0   | 60,000   | D  |  |

## **Explanation of Responses:**

1. This option shall vest in full on February 14, 2026, subject to the reporting person's continued service through the applicable vesting date.

/s/ Christina Blakley, attorney-in-02/18/2025 fact for Frederick Driscoll

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).